

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Drew M. Pardoll *et al.*

Application No.: 10/588,888

Confirmation No.: 4102

Filed: April 6, 2007

Art Unit: 1635

For: IMMUNE MODULATION BY REGULATING
EXPRESSION OF THE "MINOR" GENE IN
IMMUNE DENDRITIC CELLS

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

In response to the restriction requirement set forth in the Office Action mailed December 13, 2010, the Examiner has required restriction under 35 U.S.C. § 121 and alleges that claim 34 includes three distinct inventions and requires election between the following groups:

Group I, claim 34, drawn to a population of dendritic cell for use in vaccination of a subject produced by the process of (a) obtaining dendritic cells from an individual, (b) causing the dendritic cells to express an antigen by either (i) exposing the dendritic cells to the antigen in culture under conditions promoting uptake and processing of the antigen, or (ii) transfecting the dendritic cells with a gene encoding the antigen; (c) activating the antigen-expressing dendritic cells, (d) treating the dendritic cells with an agent that inhibits MINOR expression, wherein the agent that inhibits MINOR expression is a peptide or peptidomimetic, classifiable in class 424, subclass 134.1, for example.